Genmab beats Q1 expectations and narrows full-year guidance range
![Photo: Joost Melis / Genmab / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article14011627.ece/ALTERNATES/schema-16_9/doc7ky5nf6z0ahp39viic6.jpg)
Genmab ended Q1, 2022 with a revenue of DKK 2.1bn (USD 300m) compared to DKK 1.6bn (USD 230m) for the same period last year. The biotech company also reported an EBIT (earnings before interest and taxes) result of DKK 514m (USD 72.7m) compared to DKK 532m (USD 75m) for Q1, 2021.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Genmab enters agreement on cancer biomarker
For subscribers
Cancer drug hope raises Genmab's spirits after legal defeat
For subscribers